{"id":64294,"date":"2026-04-30T14:07:17","date_gmt":"2026-04-30T06:07:17","guid":{"rendered":"https:\/\/flcube.com\/?p=64294"},"modified":"2026-04-30T14:07:18","modified_gmt":"2026-04-30T06:07:18","slug":"regeneron-reports-19-revenue-growth-in-q1-2026-driven-by-eylea-hd-transition-and-dupixent-collaboration-strength","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64294","title":{"rendered":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength"},"content":{"rendered":"\n<p><strong>Regeneron Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>) reported <strong>first quarter 2026 financial results<\/strong> with <strong>revenues increasing 19% year-over-year (YOY) to USD 3.6 billion<\/strong> and <strong>non-GAAP net income rising 12% to USD 1.04 billion<\/strong>. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner&#8217;s National Priority Voucher program.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights-q1-2026\">Financial Highlights \u2013 Q1 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenues<\/strong><\/td><td>USD 3.6 billion<\/td><td>+19%<\/td><\/tr><tr><td><strong>Non-GAAP Net Income<\/strong><\/td><td>USD 1.04 billion<\/td><td>+12%<\/td><\/tr><tr><td><strong>Sanofi Collaboration Revenue<\/strong><\/td><td>USD 1.451 billion<\/td><td>Significant increase due to higher profit share<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>Not specified in announcement<\/td><td>Consistent with innovation-focused strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-performance\">Product Portfolio Performance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eylea-franchise-transition\">EYLEA Franchise Transition<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EYLEA HD (aflibercept)<\/strong>: Net product sales surged <strong>52% YOY to USD 468 million<\/strong>, demonstrating rapid market adoption<\/li>\n\n\n\n<li><strong>Original EYLEA<\/strong>: Sales declined <strong>36% to USD 473 million<\/strong>, reflecting successful patient transition to the high-dose formulation<\/li>\n\n\n\n<li><strong>Strategic Impact<\/strong>: Portfolio optimization maintaining overall franchise strength while extending patent protection timeline<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-immuno-oncology-growth\">Immuno-Oncology Growth<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Libtayo (cemiplimab)<\/strong>: Global sales reached <strong>USD 438 million<\/strong>, representing <strong>54% YOY growth<\/strong> across multiple indications including NSCLC, CSCC, and BCC<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-gene-therapy-milestone\">Gene Therapy Milestone<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Otarmeni (lunsotogene parvec)<\/strong>: Received <strong>accelerated FDA approval in April 2026<\/strong> as the <strong>first gene therapy approved under the Commissioner&#8217;s National Priority Voucher (CNPV) program<\/strong><\/li>\n\n\n\n<li><strong>Significance<\/strong>: Establishes Regeneron&#8217;s entry into the gene therapy space with regulatory precedent-setting approval pathway<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-collaboration-strength\">Sanofi Collaboration Strength<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Q1 Collaboration Revenue<\/strong><\/td><td>USD 1.451 billion<\/td><\/tr><tr><td><strong>Profit Share Adjustment<\/strong><\/td><td>Increased company share of antibody commercialization profits<\/td><\/tr><tr><td><strong>Dupixent Performance<\/strong><\/td><td>Global net sales (Sanofi-reported) increased <strong>33% to USD 4.9 billion<\/strong><\/td><\/tr><tr><td><strong>Therapeutic Areas<\/strong><\/td><td>Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Collaboration remains cornerstone of Regeneron&#8217;s revenue diversification strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications-amp-strategic-outlook\">Market Implications &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong>: Successful management of EYLEA lifecycle transition demonstrates strategic planning for patent cliff mitigation<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Otarmeni approval validates Regeneron&#8217;s expansion beyond traditional biologics into advanced therapy modalities<\/li>\n\n\n\n<li><strong>Financial Resilience<\/strong>: Strong collaboration revenue provides stable cash flow to fund internal R&amp;D investments across multiple therapeutic areas<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: EYLEA HD&#8217;s rapid adoption suggests effective physician education and payer acceptance strategies<\/li>\n\n\n\n<li><strong>Growth Trajectory<\/strong>: Continued double-digit growth across key franchises positions Regeneron for sustained market leadership in ophthalmology and immunology<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, product adoption rates, and strategic initiatives. Actual results may differ due to risks including competitive pressures, regulatory developments, and market dynamics affecting pharmaceutical pricing and reimbursement.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/Regeneron-Reports-First-Quarter-2026-Financial-and-Operating-Results.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Regeneron Reports First Quarter 2026 Financial and Operating Results.\"><\/object><a id=\"wp-block-file--media-c4705f96-5952-4839-b8e5-bdcc40b98c9c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/Regeneron-Reports-First-Quarter-2026-Financial-and-Operating-Results.pdf\">Regeneron Reports First Quarter 2026 Financial and Operating Results<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/Regeneron-Reports-First-Quarter-2026-Financial-and-Operating-Results.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c4705f96-5952-4839-b8e5-bdcc40b98c9c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64297,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1166,1426],"class_list":["post-64294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nasdaq-regn","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner&#039;s National Priority Voucher program.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64294\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength\" \/>\n<meta property=\"og:description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner&#039;s National Priority Voucher program.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64294\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:07:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T06:07:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength\",\"datePublished\":\"2026-04-30T06:07:17+00:00\",\"dateModified\":\"2026-04-30T06:07:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3001.webp\",\"keywords\":[\"Finanical Reports\",\"NASDAQ: REGN\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64294#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64294\",\"name\":\"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3001.webp\",\"datePublished\":\"2026-04-30T06:07:17+00:00\",\"dateModified\":\"2026-04-30T06:07:18+00:00\",\"description\":\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner's National Priority Voucher program.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64294\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64294#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength - Insight, China&#039;s Pharmaceutical Industry","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner's National Priority Voucher program.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64294","og_locale":"en_US","og_type":"article","og_title":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength","og_description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner's National Priority Voucher program.","og_url":"https:\/\/flcube.com\/?p=64294","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:07:17+00:00","article_modified_time":"2026-04-30T06:07:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64294#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64294"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength","datePublished":"2026-04-30T06:07:17+00:00","dateModified":"2026-04-30T06:07:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64294"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64294#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp","keywords":["Finanical Reports","NASDAQ: REGN","Regeneron Pharmaceuticals"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64294#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64294","url":"https:\/\/flcube.com\/?p=64294","name":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64294#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64294#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp","datePublished":"2026-04-30T06:07:17+00:00","dateModified":"2026-04-30T06:07:18+00:00","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner's National Priority Voucher program.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64294#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64294"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64294#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp","width":1080,"height":608,"caption":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64294#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64294"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64294\/revisions"}],"predecessor-version":[{"id":64298,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64294\/revisions\/64298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64297"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}